Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $253000.0.

  • CytomX Therapeutics' Cash from Financing Activities changed N/A to $253000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $96.1 million, marking a year-over-year increase of 164101.87%. This contributed to the annual value of $7.5 million for FY2024, which is 7511.74% down from last year.
  • Per CytomX Therapeutics' latest filing, its Cash from Financing Activities stood at $253000.0 for Q3 2025.
  • In the past 5 years, CytomX Therapeutics' Cash from Financing Activities registered a high of $108.7 million during Q1 2021, and its lowest value of $7000.0 during Q1 2022.
  • Over the past 5 years, CytomX Therapeutics' median Cash from Financing Activities value was $451000.0 (recorded in 2022), while the average stood at $16.2 million.
  • In the last 5 years, CytomX Therapeutics' Cash from Financing Activities skyrocketed by 494102.92% in 2021 and then plummeted by 9999.36% in 2022.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Cash from Financing Activities stood at $683000.0 in 2021, then crashed by 72.18% to $190000.0 in 2022, then grew by 28.42% to $244000.0 in 2023, then surged by 821.72% to $2.2 million in 2024, then crashed by 88.75% to $253000.0 in 2025.
  • Its last three reported values are $253000.0 in Q3 2025, $93.6 million for Q2 2025, and $2.2 million during Q4 2024.